TickerFacts.

Compare

Macrogenics Inc vs Elite Pharmaceuticals Inc vs Karyopharm Therapeutics Inc. vs Heron Therapeutics, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearMacrogenics Inc
MGNX		Elite Pharmaceuticals Inc
ELTP		Karyopharm Therapeutics Inc.
KPTI		Heron Therapeutics, Inc.
HRTX
Year ended2025-12-312026-03-312025-12-312025-12-31
Revenue$149.50M$148.87M$146.07M$154.90M
Revenue growth (YoY)-0.3%+77.1%+0.6%+7.4%
Gross marginn/a50.4%n/a73.3%
Operating margin-48.7%33.0%-62.1%-1.6%
Net margin-49.9%30.1%-134.2%-13.0%
Net income-$74.62M$44.87M-$196.04M-$20.20M
EPS (Diluted)-$1.18$0.03-$17.93-$0.12
Operating cash flow-$81.04M$23.75M-$75.37M-$27.59M
Free cash flow-$82.95M$22.82M-$75.37M-$27.91M
Cash & equivalents$57.22Mn/a$60.54M$28.65M
Total assets$256.85M$138.29M$108.42M$255.88M
Total liabilities$201.25M$39.41M$401.34M$241.54M
Shareholders' equity$55.59M$98.88M-$292.93M$14.33M
Return on year-end equity-134.2%45.4%n/a-140.9%
Shares outstanding63.32M1.08B18.31M188.31M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearMacrogenics IncElite Pharmaceuticals IncKaryopharm Therapeutics Inc.Heron Therapeutics, Inc.
Latest$149.50M
Ended 2025-12-31		$148.87M
Ended 2026-03-31		$146.07M
Ended 2025-12-31		$154.90M
Ended 2025-12-31
1 year earlier$149.96M
Ended 2024-12-31		$84.04M
Ended 2025-03-31		$145.24M
Ended 2024-12-31		$144.28M
Ended 2024-12-31
2 years earlier$58.75M
Ended 2023-12-31		$56.63M
Ended 2024-03-31		$146.03M
Ended 2023-12-31		$127.04M
Ended 2023-12-31
3 years earlier$151.94M
Ended 2022-12-31		$34.16M
Ended 2023-03-31		$157.07M
Ended 2022-12-31		$107.67M
Ended 2022-12-31
4 years earlier$77.45M
Ended 2021-12-31		$32.26M
Ended 2022-03-31		$209.82M
Ended 2021-12-31		$86.35M
Ended 2021-12-31